Strata Trial is evaluating the clinical benefit of systematic comprehensive genomic profiling and quantitative RNA expression profiling (including multivariate algorithms) for participants with advanced cancer using real-world data and endpoints, while assessing the proportion of participants available for clinical trials and approved targeted therapies in advanced and/or aggressive cancers.
Who is eligible?
The Strata Trial is enrolling patients who are 18 years or older who have been diagnosed with an advanced or metastatic solid tumor. Patients must either have already had their tumor sequenced by Strata Oncology or plan to do so within 28 days. Additional eligibility criteria must also be met.
Learn more about Strata’s testing platform that uses a single small tissue sample to provide treatment selection across therapeutic modalities.